20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Boehringer Ingelheim and Eli Lilly And Co (NYSE:LLY) said their diabetes drug Jardiance showed to slow the progression of chronic kidney disease.
- The companies said the EMPA-KIDNEY phase 3 trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for chronic kidney disease.
- In March, the trial was stopped early because an independent monitoring panel found the drug's benefit to be sufficiently clear.
- When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% vs. placebo.
- The results were announced today during the American Society of Nephrology (ASN)'s Kidney Week 2022.
- EMPA-KIDNEY trial also demonstrated a significant reduction in all-cause hospitalizations (14%) vs. placebo, one of the pre-specified key secondary confirmatory endpoints.
- The overall safety data was generally consistent with previous findings, confirming the well-established safety profile of Jardiance.
- Reductions in other key secondary endpoints of hospitalization for heart failure, cardiovascular death, or all-cause death were not statistically significant. However, the power to detect this was limited by the number of events observed.
- Price Action: LLY shares are down 0.79% at $358.82 on the last check Friday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!